Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030922 | 0.90 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9352754 | 0.89 | LMNA (0.58) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9352711 | 0.88 | LMNA (0.52) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL10305666 | 0.88 | LMNA (0.51) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL10044836 | 0.88 | LMNA (0.57) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL10624509 | 0.87 | LMNA (0.57) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9581262 | 0.86 | LMNA (0.57) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL23817080 | 0.86 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8375526 | 0.86 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9188727 | 0.86 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2151/4885CYP2C19 4077/4885HIF1A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.